{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T19:57:37Z","timestamp":1792439857437,"version":"4.5.0"},"update-to":[{"DOI":"10.1002\/14651858.cd012929","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2021,10,19]],"date-time":"2021-10-19T00:00:00Z","timestamp":1634601600000}}],"reference-count":235,"publisher":"Wiley","issue":"10","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd012929.pub2","type":"journal-article","created":{"date-parts":[[2021,10,20]],"date-time":"2021-10-20T18:41:16Z","timestamp":1634755276000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Anti-interleukin-13 and anti-interleukin-4 agents versus placebo, anti-interleukin-5 or anti-immunoglobulin-E agents, for people with asthma"],"prefix":"10.1002","volume":"2021","author":[{"given":"Andrew","family":"Gallagher","sequence":"additional","affiliation":[{"name":"Lancaster Medical Practice; Lancaster UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michaela","family":"Edwards","sequence":"additional","affiliation":[{"name":"Nottingham Business School; Nottingham Trent University; Nottingham UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parameswaran","family":"Nair","sequence":"additional","affiliation":[{"name":"Firestone Institute for Respiratory Health; McMaster University & St Joseph`s Healthcare; Hamilton Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stewart","family":"Drew","sequence":"additional","affiliation":[{"name":"Children\u2019s Physiotherapy Service; Lancashire Care NHS Foundation Trust; Preston UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aashish","family":"Vyas","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine; Lancashire Teaching Hospitals Trust; Preston UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rashmi","family":"Sharma","sequence":"additional","affiliation":[{"name":"Department of Microbiology; BTH NHS Foundation Trust; Blackpool UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul A","family":"Marsden","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine; Lancashire Teaching Hospitals Trust; Preston UK"},{"name":"North West Lung Centre; Wythenshawe Hospital, Manchester University NHS Foundation Trust; Manchester UK"},{"name":"Division of Infection, Immunity and Respiratory Medicine; School of Biological Sciences, University of Manchester; Manchester UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ran","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine; Manchester University NHS Foundation Trust; Manchester UK"},{"name":"Division of Infection, Immunity and Respiratory Medicine, School of Biological Sciences; University of Manchester; Manchester UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David JW","family":"Evans","sequence":"additional","affiliation":[{"name":"Lancaster Medical School; Lancaster University; Lancaster UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2021,10,19]]},"reference":[{"key":"10.1002\/14651858.CD012929.pub2-BIB0001|cit1","unstructured":"Borish LC Nelson HS Bensch G Corren J Busse W Whitmore J Phase I\/II study of soluble interleukin-4 receptor (il-4r) in adults with moderate asthma European Respiratory Society 9th Annual Congress; 1999 Oct 9-13; Madrid 1999 P1983"},{"issue":"3 Suppl","key":"10.1002\/14651858.CD012929.pub2-BIB0002|cit2","first-page":"A504","article-title":"Phase I\/II study of recombinant interleukin-4 receptor (IL-4R) in adult patients with moderate asthma","volume":"161","author":"Borish","year":"2000","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"3 Suppl","key":"10.1002\/14651858.CD012929.pub2-BIB0003|cit3","first-page":"A457","article-title":"Phase I\/II study of interleukin-4 receptor (IL-4R) in moderate asthma","volume":"157","author":"Borish","year":"1998","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"6","key":"10.1002\/14651858.CD012929.pub2-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1164\/ajrccm.160.6.9808146","article-title":"Interleukin-4 receptor in moderate atopic asthma. A phase I\/II randomized, placebo-controlled trial","volume":"160","author":"Borish","year":"1999","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"6","key":"10.1002\/14651858.CD012929.pub2-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1067\/mai.2001.115624","article-title":"Efficacy of soluble IL-4 receptor for the treatment of adults with asthma","volume":"107","author":"Borish","year":"2001","journal-title":"Journal of Allergy and Clinical Immunology"},{"issue":"9","key":"10.1002\/14651858.CD012929.pub2-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/S2213-2600(15)00197-6","article-title":"Efficacy and safety of tralokinumab in patients with severe uncontrolled asthma: a randomised, double-blind, placebo-controlled, phase 2b trial","volume":"3","author":"Brightling","year":"2015","journal-title":"Lancet Respiratory Medicine"},{"key":"10.1002\/14651858.CD012929.pub2-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1164\/rccm.201511-2224LE","article-title":"Effect of anti-IL-13 treatment on airway dimensions in severe asthma","volume":"194","author":"Brightling","year":"2015","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"1","key":"10.1002\/14651858.CD012929.pub2-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1164\/rccm.201511-2224LE","article-title":"Effect of anti-IL-13 treatment on airway dimensions in severe asthma","volume":"194","author":"Brightling","year":"2016","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"Suppl 61","key":"10.1002\/14651858.CD012929.pub2-BIB0009|cit9","first-page":"PA4683","article-title":"Effect of tralokinumab on GINA control in severe, uncontrolled asthma","volume":"50","author":"Brightling","year":"2017","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD012929.pub2-BIB0010|cit10","first-page":"A6670","article-title":"Efficacy and safety of tralokinumab, an anti-IL-13 monoclonal antibody, in a phase 2B study of uncontrolled severe asthma","volume":"189","author":"Brightling","year":"2014","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1002\/14651858.CD012929.pub2-BIB0011|cit11","unstructured":"A clinical trial to investigate the effects of tralokinumab, a drug used in clinical research, in adults with uncontrolled, severe asthma, a disease that causes variable and recurring inflammation of the airways leading to difficulty in breathing www.clinicaltrialsregister.eu\/ctr-search\/search?query=eudract_number:2011-001360-21"},{"issue":"Suppl 59","key":"10.1002\/14651858.CD012929.pub2-BIB0012|cit12","first-page":"OA1770","article-title":"Effect of tralokinumab on serum periostin and IgE levels in uncontrolled severe asthma","volume":"46","author":"Ranade","year":"2015","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD012929.pub2-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.ebiom.2018.07.035","article-title":"Randomized study of the safety and pharmacodynamics of inhaled interleukin-13 monoclonal antibody fragment VR942","volume":"35","author":"Burgess","year":"2018","journal-title":"Ebiomedicine"},{"key":"10.1002\/14651858.CD012929.pub2-BIB0014|cit14","first-page":"A4681","article-title":"A randomised, double-blind, placebo-controlled, dose-escalation study to evaluate the safety, tolerability, pharmacodynamics and pharmacokinetics of single inhaled doses of VR942 (UCB4144) in healthy subjects and repeated doses in mild asthmatics","volume":"195","author":"Burgess","year":"2017","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1002\/14651858.CD012929.pub2-BIB0015|cit15","first-page":"PA602","article-title":"Oral corticosteroid (OCS)-sparing effect of tralokinumab in severe, uncontrolled asthma: the TROPOS study","volume":"52","author":"Busse","year":"2018","journal-title":"European Respiratory Journal"},{"issue":"2","key":"10.1002\/14651858.CD012929.pub2-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"1800948","DOI":"10.1183\/13993003.00948-2018","article-title":"Tralokinumab did not demonstrate oral corticosteroid-sparing effects in severe asthma","volume":"53","author":"Busse","year":"2019","journal-title":"European Respiratory Journal"},{"issue":"8","key":"10.1002\/14651858.CD012929.pub2-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"723","DOI":"10.4155\/cli.15.37","article-title":"TROPOS: designing a clinical trial to evaluate the oral corticosteroid-sparing effect of a biologic in severe asthma","volume":"5","author":"Busse","year":"2015","journal-title":"Clinical Investigation"},{"key":"10.1002\/14651858.CD012929.pub2-BIB0018|cit18","unstructured":"Phase 3 study to evaluate the efficacy & safety of tralokinumab in adults & adolescents with OCS dependent asthma clinicaltrials.gov\/show\/NCT02281357"},{"key":"10.1002\/14651858.CD012929.pub2-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"AB101","DOI":"10.1016\/j.jaci.2018.12.307","article-title":"Dupilumab consistently improves rhinoconjunctivitis-specific health-related quality of life in patients with uncontrolled, moderate-to-severe asthma and comorbid allergic rhinitis: results from the phase 3 LIBERTY ASTHMA QUEST study","volume":"143","author":"Bousquet","year":"2019","journal-title":"Journal of Allergy and Clinical Immunology"},{"key":"10.1002\/14651858.CD012929.pub2-BIB0020|cit20","first-page":"PA1125","article-title":"Dupilumab improves SNOT-22 scores in asthma patients with chronic rhinosinusitis or nasal polypsosis (CRS\/NP) in liberty asthma quest","volume":"52","author":"Busse","year":"2018","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD012929.pub2-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"AB21","DOI":"10.1016\/j.jaci.2019.12.792","article-title":"Baseline feno AS a prognostic biomarker for subsequent severe asthma exacerbations in patients with uncontrolled, moderate-to-severe asthma receiving placebo in the LIBERTY ASTHMA QUEST study","volume":"145","author":"Busse","year":"2020","journal-title":"Journal of Allergy and Clinical Immunology"},{"issue":"2 Suppl","key":"10.1002\/14651858.CD012929.pub2-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"AB97","DOI":"10.1016\/j.jaci.2018.12.296","article-title":"Dupilumab improves lung function and reduces severe exacerbation rate in patients with uncontrolled, moderate-to-severe asthma with or without comorbid allergic rhinitis: results from the phase 3 LIBERTY ASTHMA QUEST study","volume":"143","author":"Busse","year":"2019","journal-title":"Journal of Allergy and Clinical Immunology"},{"issue":"5","key":"10.1002\/14651858.CD012929.pub2-BIB0023|cit23","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/j.anai.2020.05.026","article-title":"Efficacy of dupilumab on clinical outcomes in patients with asthma and perennial allergic rhinitis","volume":"125","author":"Busse","year":"2020","journal-title":"Annals of Allergy, Asthma & Immunology"},{"key":"10.1002\/14651858.CD012929.pub2-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1007\/s12325-018-0702-4","article-title":"Liberty Asthma QUEST: phase 3 randomized, double-blind, placebo-controlled, parallel-group study to evaluate dupilumab efficacy\/safety in patients with uncontrolled, moderate-to-severe asthma","volume":"35","author":"Busse","year":"2018","journal-title":"Advances in Therapy"},{"issue":"5","key":"10.1002\/14651858.CD012929.pub2-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12325-018-0702-4","article-title":"Liberty asthma QUEST: phase 3 randomized, double-blind, placebo-controlled, parallel-group study to evaluate dupilumab efficacy\/safety in patients with uncontrolled, moderate-to-severe asthma","volume":"35","author":"Busse","year":"2018","journal-title":"Advances in Therapy"},{"key":"10.1002\/14651858.CD012929.pub2-BIB0026|cit26","first-page":"A21","article-title":"Dupilumab reduces severe exacerbations across baseline disease characteristics in patients with elevated baseline type 2 biomarkers: the LIBERTY ASTHMA QUEST study","volume":"74","author":"Busse","year":"2019","journal-title":"Thorax"},{"key":"10.1002\/14651858.CD012929.pub2-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"S39","DOI":"10.1016\/j.anai.2019.08.289","article-title":"Dupilumab improved asthma control across baseline immunoglobulin e levels: Liberty Asthma Quest study","volume":"123","author":"Carr","year":"2019","journal-title":"Annals of Allergy, Asthma and Immunology"},{"key":"10.1002\/14651858.CD012929.pub2-BIB0028|cit28","first-page":"A6163","article-title":"Dupilumab treatment produces rapid and sustained improvements in FEV1 in patients with uncontrolled, moderate-to-severe asthma from the LIBERTY ASTHMA QUEST study","volume":"197","author":"Castro","year":"2018","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"Suppl 63","key":"10.1002\/14651858.CD012929.pub2-BIB0029|cit29","first-page":"PA540","article-title":"Dupilumab effect on lung function in patients with uncontrolled, moderate-to-severe asthma with an allergic phenotype","volume":"54","author":"Castro","year":"2019","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD012929.pub2-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"S8","DOI":"10.1016\/j.anai.2018.09.021","article-title":"Dupilumab efficacy in uncontrolled, moderate-to-severe allergic asthma in the phase 3 Liberty Asthma Quest study","volume":"5 Suppl","author":"Castro","year":"2018","journal-title":"Annals of Allergy, Asthma and Immunology"},{"key":"10.1002\/14651858.CD012929.pub2-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1056\/NEJMoa1804092","article-title":"Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma","volume":"378","author":"Castro","year":"2018","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD012929.pub2-BIB0032|cit32","first-page":"A7700","article-title":"A randomized, controlled phase 3 study, LIBERTY ASTHMA QUEST, evaluating the efficacy and safety of dupilumab in uncontrolled moderate-to-severe asthma","volume":"197","author":"Castro","year":"2018","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1002\/14651858.CD012929.pub2-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"A936","DOI":"10.1016\/j.chest.2019.08.870","article-title":"Dupilumab reduces severe asthma exacerbation rate and improves lung function regardless of age at onset of asthma: the Liberty Asthma Quest study","volume":"156","author":"Castro","year":"2019","journal-title":"Chest"},{"issue":"1","key":"10.1002\/14651858.CD012929.pub2-BIB0034|cit34","first-page":"00204","article-title":"Dupilumab improves lung function in patients with uncontrolled, moderate-to-severe asthma","volume":"6","author":"Castro","year":"2020","journal-title":"European Respiratory Journal Open Research"},{"key":"10.1002\/14651858.CD012929.pub2-BIB0035|cit35","first-page":"9","article-title":"Dupilumab improved lung function in patients with uncontrolled, moderate-to-severe asthma","volume":"199","author":"Castro","year":"2019","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"2 Suppl","key":"10.1002\/14651858.CD012929.pub2-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"AB97","DOI":"10.1016\/j.jaci.2018.12.297","article-title":"Dupilumab suppresses inflammatory biomarkers in asthma patients with or without allergic rhinitis: post hoc analysis of the LIBERTY ASTHMA QUEST study","volume":"143","author":"Corren","year":"2019","journal-title":"Journal of Allergy and Clinical Immunology"},{"key":"10.1002\/14651858.CD012929.pub2-BIB0037|cit37","first-page":"A5948","article-title":"Dupilumab produces rapid and sustained improvements in asthma-related symptoms in patients with uncontrolled, moderate-to-severe asthma from the LIBERTY ASTHMA QUEST study","volume":"197","author":"Corren","year":"2018","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1002\/14651858.CD012929.pub2-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"S42","DOI":"10.1016\/j.anai.2018.09.136","article-title":"Dupilumab improves asthma control in patients with uncontrolled, moderate-to-severe asthma, regardless of exacerbation history","volume":"5 Suppl","author":"Corren","year":"2018","journal-title":"Annals of Allergy, Asthma and Immunology"},{"issue":"Suppl 62","key":"10.1002\/14651858.CD012929.pub2-BIB0039|cit39","first-page":"PA1124","article-title":"Dupilumab improves asthma-related patient reported outcomes in asthma patients with chronic rhinosinusitis or nasal polyposis (CRS\/NP) in Liberty Asthma Quest","volume":"52","author":"Corren","year":"2018","journal-title":"European Respiratory Journal"},{"issue":"2","key":"10.1002\/14651858.CD012929.pub2-BIB0040|cit40","first-page":"516","article-title":"Dupilumab efficacy in patients with uncontrolled, moderate-to-severe allergic asthma","volume":"8","author":"Corren","year":"2019","journal-title":"Journal of Allergy and Clinical Immunology"},{"issue":"5","key":"10.1002\/14651858.CD012929.pub2-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"S15, D201","DOI":"10.1016\/j.anai.2019.08.071","article-title":"Dupilumab efficacy in patients with uncontrolled, moderate-to-severe asthma and serologic evidence of allergic bronchopulmonary aspergillosis","volume":"123","author":"Corren","year":"2019","journal-title":"Annals of Allergy, Asthma and Immunology"},{"issue":"Suppl 6","key":"10.1002\/14651858.CD012929.pub2-BIB0042|cit42","first-page":"22","article-title":"Dupilumab demonstrates rapid and sustained improvements in daily asthma-related symptoms in patients with uncontrolled, moderate-to-severe asthma: data from the Liberty Asthma Quest study","volume":"48","author":"Douglass","year":"2018","journal-title":"Internal Medicine Journal"},{"key":"10.1002\/14651858.CD012929.pub2-BIB0043|cit43","unstructured":"Evaluation of dupilumab in patients with persistent asthma (Liberty Asthma Quest) www.clinicaltrialsregister.eu\/ctr-search\/search?query=eudract_number:2014-004940-36"},{"key":"10.1002\/14651858.CD012929.pub2-BIB0044|cit44","first-page":"30","article-title":"Efficacy of dupilumab in patients with type 2 inflammatory asthma enrolled in the Liberty Asthma QUEST study","volume":"4","author":"FitzGerald","year":"2020","journal-title":"Canadian Journal of Respiratory, Critical Care, and Sleep Medicine"},{"issue":"Suppl 105","key":"10.1002\/14651858.CD012929.pub2-BIB0045|cit45","first-page":"464","article-title":"Dupilumab reduces exacerbations and improves lung function in uncontrolled, moderate-to-severe asthma patients across prior historical exacerbation subgroups in the phase 3 LIBERTY ASTHMA QUEST study","volume":"73","author":"Ford","year":"2018","journal-title":"European Journal of Allergy and Clinical Immunology"},{"key":"10.1002\/14651858.CD012929.pub2-BIB0046|cit46","first-page":"9","article-title":"Dupilumab improved asthma control and health-related quality of life in patients with oral-corticosteroid-dependent severe asthma in the phase 3 LIBERTY ASTHMA VENTURE study","volume":"199","author":"Ford","year":"2019","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1002\/14651858.CD012929.pub2-BIB0047|cit47","first-page":"9","article-title":"Dupilumab reduces severe exacerbations and improves lung function in late-onset, uncontrolled, moderate-to-severe asthma patients enrolled in the LIBERTY ASTHMA QUEST study","volume":"199","author":"Hanania","year":"2019","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD012929.pub2-BIB0048|cit48","first-page":"110","article-title":"Dupilumab improves asthma outcomes regardless of baseline lung function","volume":"24","author":"Katelaris","year":"2019","journal-title":"Respirology"},{"issue":"Suppl 63","key":"10.1002\/14651858.CD012929.pub2-BIB0049|cit49","first-page":"PA2753","article-title":"Dupilumab efficacy in patients with uncontrolled, moderate-to-severe asthma by body mass index","volume":"54","author":"Korn","year":"2019","journal-title":"European Respiratory Journal"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD012929.pub2-BIB0050|cit50","doi-asserted-by":"publisher","first-page":"P04","DOI":"10.1055\/s-0039-1678039","article-title":"Dupilumab improved asthma control in patients with uncontrolled, moderate-to-severe asthma, regardless of exacerbations in the previous year","volume":"73","author":"Korn","year":"2019","journal-title":"Pneumologie"},{"issue":"Suppl 105","key":"10.1002\/14651858.CD012929.pub2-BIB0051|cit51","first-page":"30","article-title":"Dupilumab improves health related quality of life in uncontrolled, moderate-to-severe asthma patients with comorbid allergic rhinitis from the phase 3 LIBERTY ASTHMA QUEST study","volume":"73","author":"Maspero","year":"2018","journal-title":"European Journal of Allergy and Clinical Immunology"},{"issue":"2 Suppl","key":"10.1002\/14651858.CD012929.pub2-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"AB98","DOI":"10.1016\/j.jaci.2018.12.299","article-title":"Dupilumab suppresses type 2 biomarkers in asthma patients with and without comorbid chronic rhinosinusitis with or without nasal polyposis (CRS\/NP): post hoc analysis of LIBERTY ASTHMA QUEST","volume":"143","author":"Maspero","year":"2019","journal-title":"Journal of Allergy and Clinical Immunology"},{"key":"10.1002\/14651858.CD012929.pub2-BIB0053|cit53","first-page":"527","article-title":"Dupilumab efficacy in uncontrolled, moderate-to-severe asthma with self-reported chronic rhinosinusitis","volume":"8","author":"Maspero","year":"2020","journal-title":"Journal of Allergy and Clinical Immunology"},{"key":"10.1002\/14651858.CD012929.pub2-BIB0054|cit54","unstructured":"Evaluation of dupilumab in patients with persistent asthma (Liberty Asthma Quest) clinicaltrials.gov\/show\/NCT02414854"},{"key":"10.1002\/14651858.CD012929.pub2-BIB0055|cit55","first-page":"A33","article-title":"Dupilumab improves lung function across baseline disease characteristics in patients with evidence of type 2 inflammation at baseline: the Liberty Asthma Quest study","volume":"74","author":"Paggiaro","year":"2019","journal-title":"Thorax"},{"issue":"Suppl 63","key":"10.1002\/14651858.CD012929.pub2-BIB0056|cit56","first-page":"PA538","article-title":"Dupilumab efficacy in asthma patients with FEV1 60-80% predicted on medium-DOSE ICS: Liberty Asthma Quest study","volume":"54","author":"Papi","year":"2019","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD012929.pub2-BIB0057|cit57","first-page":"9","article-title":"Dupilumab reduces severe exacerbations and improves lung function regardless of baseline bronchodilator reversibility in patients with uncontrolled moderate-to-severe asthma enrolled in the LIBERTY ASTHMA QUEST study","volume":"199","author":"Pavord","year":"2019","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"Suppl 105","key":"10.1002\/14651858.CD012929.pub2-BIB0058|cit58","first-page":"463","article-title":"Dupilumab reduces risk of severe exacerbations and improves FEV1 in patients on both high-and medium dose ICS with uncontrolled, moderate-to-severe asthma from the phase 3 LIBERTY ASTHMA QUEST study","volume":"73","author":"Pavord","year":"2018","journal-title":"European Journal of Allergy and Clinical Immunology"},{"issue":"Suppl 63","key":"10.1002\/14651858.CD012929.pub2-BIB0059|cit59","first-page":"A3807","article-title":"Dupilumab efficacy in type 2 inflammatory asthma: Liberty Asthma QUEST study","volume":"54","author":"Pavord","year":"2019","journal-title":"European Respiratory Journal"},{"issue":"Suppl 62","key":"10.1002\/14651858.CD012929.pub2-BIB0060|cit60","first-page":"OA1651","article-title":"Dupilumab efficacy in asthma patients with comorbid chronic rhinosinusitis or nasal polyposis (CRS\/NP) in LIBERTY ASTHMA QUEST","volume":"52","author":"Pavord","year":"2018","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD012929.pub2-BIB0061|cit61","first-page":"9","article-title":"Dupilumab improved lung function in patients with uncontrolled, moderate-to-severe asthma despite exacerbation events during the LIBERTY ASTHMA QUEST study","volume":"199","author":"Rabe","year":"2019","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"4","key":"10.1002\/14651858.CD012929.pub2-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/j.alit.2020.04.002","article-title":"Dupilumab efficacy and safety in Japanese patients with uncontrolled, moderate-to-severe asthma in the phase 3 LIBERTY ASTHMA QUEST study","volume":"69","author":"Tohda","year":"2020","journal-title":"Allergology International"},{"issue":"Suppl 62","key":"10.1002\/14651858.CD012929.pub2-BIB0063|cit63","first-page":"PA5005","article-title":"Dupilumab shows rapid and sustained suppression of inflammatory biomarkers in asthma patients in Liberty Asthma Quest","volume":"52","author":"Wenzel","year":"2018","journal-title":"European Respiratory Journal"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD012929.pub2-BIB0064|cit64","first-page":"S69","article-title":"Semi-mechanistic pharmacokinetic\/pharmacodynamic (PK\/PD) modeling of dupilumab on pre-bronchodilator forced expiratory volume in 1 second (FEV1) in uncontrolled moderate-to-severe asthma","volume":"45","author":"Zhang","year":"2018","journal-title":"Journal of Pharmacokinetics and Pharmacodynamics"},{"issue":"8","key":"10.1002\/14651858.CD012929.pub2-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1164\/rccm.200909-1448OC","article-title":"A randomized, controlled, phase 2 study of AMG 317, an IL-4Ralpha antagonist, in patients with asthma","volume":"181","author":"Corren","year":"2010","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"2 Suppl 1","key":"10.1002\/14651858.CD012929.pub2-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"AB13","DOI":"10.1016\/j.jaci.2015.12.043","article-title":"Rapid lung function improvement with lebrikizumab in patients with uncontrolled asthma","volume":"137","author":"Corren","year":"2016","journal-title":"Journal of Allergy and Clinical Immunology"},{"issue":"12","key":"10.1002\/14651858.CD012929.pub2-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1056\/NEJMoa1106469","article-title":"Lebrikizumab treatment in adults with asthma","volume":"365","author":"Corren","year":"2011","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD012929.pub2-BIB0068|cit68","first-page":"A3959","article-title":"Lebrikizumab, an anti-IL-13 monoclonal antibody, reduces severe asthma exacerbations over 32 weeks in adults with inadequately controlled asthma [abstract]","volume":"185","author":"McClintock","year":"2012","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"Suppl 56","key":"10.1002\/14651858.CD012929.pub2-BIB0069|cit69","first-page":"387s [P2167]","article-title":"Lebrikizumab reduces serum periostin in asthma patients with elevated baseline periostin","volume":"40","author":"Scheerens","year":"2012","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD012929.pub2-BIB0070|cit70","first-page":"A3960","article-title":"Lebrikizumab treatment reduces serum periostin levels in asthma patients with elevated baseline levels of periostin","volume":"185","author":"Scheerens","year":"2012","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"4","key":"10.1002\/14651858.CD012929.pub2-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/j.jaci.2014.01.002","article-title":"Efficacy and safety of an anti-IL-13 mAb in patients with severe asthma: a randomized trial","volume":"133","author":"De Boever","year":"2014","journal-title":"Journal of Allergy and Clinical Immunology"},{"issue":"8","key":"10.1002\/14651858.CD012929.pub2-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1164\/rccm.201008-1210OC","article-title":"Effects of interleukin-13 blockade on allergen-induced airway responses in mild atopic asthma","volume":"183","author":"Gauvreau","year":"2011","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1002\/14651858.CD012929.pub2-BIB0073|cit73","unstructured":"Study evaluating the effects of IMA-638 on allergen-induced airway responses in subjects with mild atopic asthma clinicaltrials.gov\/show\/NCT00410280"},{"issue":"8","key":"10.1002\/14651858.CD012929.pub2-BIB0074|cit74","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1164\/rccm.201008-1210OC","article-title":"Effects of interleukin-13 blockade on allergen-induced airway responses in mild atopic asthma","volume":"183","author":"Gauvreau","year":"2011","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1002\/14651858.CD012929.pub2-BIB0075|cit75","unstructured":"Study evaluating the effects of IMA-638 on allergen-induced airway responses in subjects with mild atopic asthma clinicaltrials.gov\/show\/NCT00410280"},{"key":"10.1002\/14651858.CD012929.pub2-BIB0076|cit76","first-page":"3426","article-title":"Efficacy of an anti-IL13 monoclonal antibody, lebrikizumab, in adults with inadequately controlled asthma is enhanced in those with high periostin levels","volume":"38","author":"Hanania","year":"2011","journal-title":"European Respiratory Journal"},{"issue":"8","key":"10.1002\/14651858.CD012929.pub2-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1136\/thoraxjnl-2014-206719","article-title":"Lebrikizumab in moderate-to-severe asthma: pooled data from two randomised placebo-controlled studies","volume":"70","author":"Hanania","year":"2015","journal-title":"Thorax"},{"issue":"2 Suppl","key":"10.1002\/14651858.CD012929.pub2-BIB0078|cit78","doi-asserted-by":"crossref","first-page":"AB402","DOI":"10.1016\/j.jaci.2013.12.1064","article-title":"Efficacy and safety of lebrikizumab in severe uncontrolled asthma: results from the lute and verse phase II randomized, double-blind, placebo-controlled trials","volume":"133","author":"Hanania","year":"2014","journal-title":"Journal of Allergy and Clinical Immunology"},{"key":"10.1002\/14651858.CD012929.pub2-BIB0079|cit79","unstructured":"A study of lebrikizumab in patients whose asthma is uncontrolled with inhaled corticosteroids and a second controller medication (LUTE) clinicaltrials.gov\/show\/NCT01545440"},{"key":"10.1002\/14651858.CD012929.pub2-BIB0080|cit80","unstructured":"A study of lebrikizumab in patients with uncontrolled asthma who are on inhaled corticosteroids and a second controller medication (VERSE) clinicaltrials.gov\/show\/NCT01545453"},{"issue":"8","key":"10.1002\/14651858.CD012929.pub2-BIB0081|cit81","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1136\/thoraxjnl-2014-206719","article-title":"Lebrikizumab in moderate-to-severe asthma: pooled data from two randomised placebo-controlled studies","volume":"70","author":"Hanania","year":"2015","journal-title":"Thorax"},{"issue":"2 Suppl","key":"10.1002\/14651858.CD012929.pub2-BIB0082|cit82","doi-asserted-by":"crossref","first-page":"AB402","DOI":"10.1016\/j.jaci.2013.12.1064","article-title":"Efficacy and safety of lebrikizumab in severe uncontrolled asthma: results from the lute and verse phase II randomized, double-blind, placebo-controlled trials","volume":"133","author":"Hanania","year":"2014","journal-title":"Journal of Allergy and Clinical Immunology"},{"key":"10.1002\/14651858.CD012929.pub2-BIB0083|cit83","unstructured":"A study of lebrikizumab in patients whose asthma is uncontrolled with inhaled corticosteroids and a second controller medication (LUTE) clinicaltrials.gov\/show\/NCT01545440"},{"key":"10.1002\/14651858.CD012929.pub2-BIB0084|cit84","unstructured":"A study of lebrikizumab in patients with uncontrolled asthma who are on inhaled corticosteroids and a second controller medication (VERSE) clinicaltrials.gov\/show\/NCT01545453"},{"key":"10.1002\/14651858.CD012929.pub2-BIB0085|cit85","doi-asserted-by":"crossref","first-page":"e000406","DOI":"10.1136\/bmjresp-2019-000406","article-title":"Seasonal variability of lung function and asthma quality of life questionnaire scores in adults with uncontrolled asthma","volume":"6","author":"Bauer","year":"2019","journal-title":"BMJ Open Respiratory Research"},{"issue":"Suppl 60","key":"10.1002\/14651858.CD012929.pub2-BIB0086|cit86","first-page":"OA1975","article-title":"LAVOLTA I and II: results of 2 phase III studies to assess the efficacy and safety of lebrikizumab in patients with uncontrolled asthma","volume":"48","author":"Hanania","year":"2016","journal-title":"European Respiratory Journal"},{"issue":"10","key":"10.1002\/14651858.CD012929.pub2-BIB0087|cit87","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/S2213-2600(16)30265-X","article-title":"Efficacy and safety of lebrikizumab in patients with uncontrolled asthma (LAVOLTA I and LAVOLTA II): replicate, phase 3, randomised, double-blind, placebo-controlled trials","volume":"4","author":"Hanania","year":"2016","journal-title":"Lancet Respiratory Medicine"},{"key":"10.1002\/14651858.CD012929.pub2-BIB0088|cit88","first-page":"A1318","article-title":"LAVOLTA I and II: design and baseline characteristics of two phase III, randomized, double-blind, placebo-controlled studies to assess the efficacy and safety of lebrikizumab in adult patients with uncontrolled asthma","volume":"193","author":"Hanania","year":"2016","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1002\/14651858.CD012929.pub2-BIB0089|cit89","unstructured":"A study of lebrikizumab in participants with uncontrolled asthma who are on inhaled corticosteroids and a second controller medication clinicaltrials.gov\/show\/NCT01867125"},{"issue":"Suppl 60","key":"10.1002\/14651858.CD012929.pub2-BIB0090|cit90","first-page":"OA1975","article-title":"LAVOLTA I and II: results of 2 phase III studies to assess the efficacy and safety of lebrikizumab in patients with uncontrolled asthma","volume":"48","author":"Hanania","year":"2016","journal-title":"European Respiratory Journal"},{"issue":"10","key":"10.1002\/14651858.CD012929.pub2-BIB0091|cit91","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/S2213-2600(16)30265-X","article-title":"Efficacy and safety of lebrikizumab in patients with uncontrolled asthma (LAVOLTA I and LAVOLTA II): replicate, phase 3, randomised, double-blind, placebo-controlled trials","volume":"4","author":"Hanania","year":"2016","journal-title":"Lancet Respiratory Medicine"},{"key":"10.1002\/14651858.CD012929.pub2-BIB0092|cit92","first-page":"A1318","article-title":"LAVOLTA I and II: design and baseline characteristics of two phase III, randomized, double-blind, placebo-controlled studies to assess the efficacy and safety of lebrikizumab in adult patients with uncontrolled asthma","volume":"193","author":"Hanania","year":"2016","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1002\/14651858.CD012929.pub2-BIB0093|cit93","unstructured":"A study of lebrikizumab in participants with uncontrolled asthma who are on inhaled corticosteroids and a second controller medication clinicaltrials.gov\/show\/NCT01867125"},{"issue":"1","key":"10.1002\/14651858.CD012929.pub2-BIB0094|cit94","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1111\/j.1365-2125.2012.04334.x","article-title":"A phase 1, randomized, placebo-controlled, dose-escalation study of an anti-IL-13 monoclonal antibody in healthy subjects and mild asthmatics","volume":"75","author":"Hodsman","year":"2013","journal-title":"British Journal of Clinical Pharmacology"},{"key":"10.1002\/14651858.CD012929.pub2-BIB0095|cit95","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.rmed.2017.12.006","article-title":"Efficacy and safety of lebrikizumab in adult patients with mild-to-moderate asthma not receiving inhaled corticosteroids","volume":"134","author":"Korenblat","year":"2018","journal-title":"Respiratory Medicine"},{"key":"10.1002\/14651858.CD012929.pub2-BIB0096|cit96","first-page":"A1316","article-title":"STRETTO: design and baseline characteristics of a phase III, double-blind, placebo-controlled study to assess the efficacy and safety of lebrikizumab in adult patients with mild-to-moderate asthma","volume":"193","author":"Yen","year":"2016","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1002\/14651858.CD012929.pub2-BIB0097|cit97","unstructured":"Study evaluating the effect of IMA-638 in subjects with persistent asthma clinicaltrials.gov\/show\/NCT00425061"},{"key":"10.1002\/14651858.CD012929.pub2-BIB0098|cit98","unstructured":"A study to assess the efficacy, safety, and tolerability of CAT-354 in subjects with asthma clinicaltrials.gov\/show\/NCT00640016"},{"issue":"3","key":"10.1002\/14651858.CD012929.pub2-BIB0099|cit99","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.jaci.2013.03.051","article-title":"Dose-ranging study of lebrikizumab in asthmatic patients not receiving inhaled steroids","volume":"132","author":"Noonan","year":"2013","journal-title":"Journal of Allergy and Clinical Immunology"},{"key":"10.1002\/14651858.CD012929.pub2-BIB0100|cit100","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1007\/s40264-018-00788-w","article-title":"Evaluation of antibody properties and clinically relevant immunogenicity, anaphylaxis, and hypersensitivity reactions in two phase III trials of tralokinumab in severe, uncontrolled asthma","volume":"426","author":"Carlsson","year":"2019","journal-title":"Drug Safety"},{"key":"10.1002\/14651858.CD012929.pub2-BIB0101|cit101","unstructured":"A phase 3 study to evaluate the efficacy and safety of tralokinumab in adults and adolescents with asthma that is not controlled www.clinicaltrialsregister.eu\/ctr-search\/search?query=eudract_number:2013-005615-27"},{"key":"10.1002\/14651858.CD012929.pub2-BIB0102|cit102","unstructured":"A phase 3 study to evaluate the efficacy and safety of tralokinumab in adults and adolescents with uncontrolled asthma (STRATOS1) clinicaltrials.gov\/show\/NCT02161757"},{"key":"10.1002\/14651858.CD012929.pub2-BIB0103|cit103","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/S2213-2600(18)30184-X","article-title":"Tralokinumab for severe, uncontrolled asthma (STRATOS 1 and STRATOS 2): two randomised, double-blind, placebo-controlled, phase 3 clinical trials","volume":"6","author":"Sj\u00f6bring","year":"2018","journal-title":"Lancet Respiratory Medicine"},{"key":"10.1002\/14651858.CD012929.pub2-BIB0104|cit104","unstructured":"A phase 3 study to evaluate the efficacy and safety of tralokinumab in adults and adolescents with uncontrolled asthma (STRATOS2) clinicaltrials.gov\/show\/NCT02194699"},{"key":"10.1002\/14651858.CD012929.pub2-BIB0105|cit105","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/S2213-2600(18)30184-X","article-title":"Tralokinumab for severe, uncontrolled asthma (STRATOS 1 and STRATOS 2): two randomised, double-blind, placebo-controlled, phase 3 clinical trials","volume":"6","author":"Sj\u00f6bring","year":"2018","journal-title":"Lancet Respiratory Medicine"},{"issue":"2","key":"10.1002\/14651858.CD012929.pub2-BIB0106|cit106","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1183\/09031936.00223411","article-title":"A phase II placebo-controlled study of tralokinumab in moderate-to-severe asthma","volume":"41","author":"Piper","year":"2013","journal-title":"European Respiratory Journal"},{"issue":"55","key":"10.1002\/14651858.CD012929.pub2-BIB0107|cit107","first-page":"608s [3425]","article-title":"Phase 2 randomized, double-blind, placebo-controlled study of tralokinumab, an anti-IL-13 monoclonal antibody, in moderate to severe asthma","volume":"38","author":"Piper","year":"2011","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD012929.pub2-BIB0108|cit108","first-page":"A2759","article-title":"Subgroup analysis of a phase 2A randomized, double-blind, placebo-controlled study of tralokinumab, an anti-IL-13 monoclonal antibody, in moderate to severe asthma","volume":"185","author":"Piper","year":"2012","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1002\/14651858.CD012929.pub2-BIB0109|cit109","doi-asserted-by":"crossref","first-page":"AB173","DOI":"10.1016\/j.jaci.2019.12.361","article-title":"Dupilumab reduces oral corticosteroid use and severe exacerbations and improves lung function in patients with oral corticosteroid-dependent severe asthma with and without comorbid allergic rhinitis in the phase 3 LIBERTY ASTHMA VENTURE study","volume":"145","author":"Castro","year":"2020","journal-title":"Journal of Allergy and Clinical Immunology"},{"key":"10.1002\/14651858.CD012929.pub2-BIB0110|cit110","first-page":"27","article-title":"Dupilumab effect on asthma control and health-related quality of life in patients with oral corticosteroid-dependent severe asthma with comorbid chronic rhinosinusitis with and without nasal polyps","volume":"74","author":"Castro","year":"2019","journal-title":"European Journal of Allergy and Clinical Immunology"},{"key":"10.1002\/14651858.CD012929.pub2-BIB0111|cit111","unstructured":"Evaluation of dupilumab in patients with severe steroid dependent asthma www.clinicaltrialsregister.eu\/ctr-search\/search?query=eudract_number:2015-001573-40"},{"key":"10.1002\/14651858.CD012929.pub2-BIB0112|cit112","doi-asserted-by":"crossref","first-page":"A929","DOI":"10.1016\/j.chest.2019.08.868","article-title":"Dupilumab reduces severe exacerbations in patients with oral corticosteroid-dependent severe asthma with and without early improvements in lung function","volume":"156","author":"Hanania","year":"2019","journal-title":"Chest"},{"key":"10.1002\/14651858.CD012929.pub2-BIB0113|cit113","first-page":"35","article-title":"Dupilumab improves health-related quality of life in patients with oral corticosteroid dependent, severe asthma with comorbid chronic rhinosinusitis with and without nasal polyps","volume":"74","author":"Maspero","year":"2019","journal-title":"European Journal of Allergy and Clinical Immunology"},{"key":"10.1002\/14651858.CD012929.pub2-BIB0114|cit114","unstructured":"Evaluation of dupilumab in patients with severe steroid dependent asthma (VENTURE) clinicaltrials.gov\/show\/NCT02528214"},{"key":"10.1002\/14651858.CD012929.pub2-BIB0115|cit115","first-page":"PA5003","article-title":"Dupilumab shows rapid and sustained suppression of inflammatory biomarkers in corticosteroid (CS)-dependent severe asthma patients in Liberty Asthma venture","volume":"52","author":"Rabe","year":"2018","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD012929.pub2-BIB0116|cit116","first-page":"35","article-title":"Dupilumab reduces oral corticosteroid (OCS) use and severe exacerbations, and improves FEV1 in OCS dependent, severe asthma with comorbid chronic rhinosinusitis with and without nasal polyps","volume":"74","author":"Rabe","year":"2019","journal-title":"European Journal of Allergy and Clinical Immunology"},{"key":"10.1002\/14651858.CD012929.pub2-BIB0117|cit117","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1056\/NEJMoa1804093","article-title":"Efficacy and safety of dupilumab in glucocorticoid-dependent severe asthma","volume":"378","author":"Rabe","year":"2018","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD012929.pub2-BIB0118|cit118","first-page":"100010","article-title":"The effect of dupilumab on lung function parameters in patients with oral corticosteroid-dependent severe asthma","volume":"2","author":"Rabe","year":"2020","journal-title":"Respiratory Medicine"},{"key":"10.1002\/14651858.CD012929.pub2-BIB0119|cit119","first-page":"A7712","article-title":"Dupilumab in patients with corticosteroid-dependent severe asthma: efficacy and safety results from the randomized, double-blind, placebo-controlled phase 3 Liberty Asthma venture study","volume":"197","author":"Rabe","year":"2018","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1002\/14651858.CD012929.pub2-BIB0120|cit120","first-page":"A2669","article-title":"Dupilumab improved morning and evening daily asthma symptoms in patients with oral-corticosteroid-dependent severe asthma in the phase 3 LIBERTY ASTHMA VENTURE study","volume":"199","author":"Sher","year":"2019","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1002\/14651858.CD012929.pub2-BIB0121|cit121","unstructured":"A phase 2 study to evaluate the effect of tralokinumab in adults with asthma inadequately controlled on inhaled corticosteroid www.clinicaltrialsregister.eu\/ctr-search\/search?query=eudract_number:2015-000857-19"},{"key":"10.1002\/14651858.CD012929.pub2-BIB0122|cit122","unstructured":"Study to evaluate efficacy & safety of tralokinumab in subjects with asthma inadequately controlled on corticosteroids (MESOS) clinicaltrials.gov\/show\/NCT02449473"},{"issue":"7","key":"10.1002\/14651858.CD012929.pub2-BIB0123|cit123","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/S2213-2600(18)30201-7","article-title":"Effect of tralokinumab, an interleukin-13 neutralising monoclonal antibody, on eosinophilic airway inflammation in uncontrolled moderate-to-severe asthma (MESOS): a multicentre, double-blind, randomised, placebo-controlled phase 2 trial","volume":"6","author":"Russell","year":"2018","journal-title":"Lancet Respiratory Medicine"},{"key":"10.1002\/14651858.CD012929.pub2-BIB0124|cit124","first-page":"A7714","article-title":"Effect of tralokinumab upon eosinophilic airway inflammation in participants with moderate to severe, uncontrolled asthma (MESOS) study","volume":"197","author":"Russell","year":"2018","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"2 Suppl 1","key":"10.1002\/14651858.CD012929.pub2-BIB0125|cit125","first-page":"AB164","article-title":"Predictive and pharmacodynamic biomarkers of interleukin-13 blockade: effect of lebrikizumab on late phase asthmatic response to allergen challenge [abstract]","volume":"127","author":"Scheerens","year":"2011","journal-title":"Journal of Allergy and Clinical Immunology"},{"issue":"1","key":"10.1002\/14651858.CD012929.pub2-BIB0126|cit126","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1111\/cea.12220","article-title":"The effects of lebrikizumab in patients with mild asthma following whole lung allergen challenge","volume":"44","author":"Scheerens","year":"2014","journal-title":"Clinical and Experimental Allergy"},{"key":"10.1002\/14651858.CD012929.pub2-BIB0127|cit127","unstructured":"Bhowmick B Singh D Molfino N Cranmer H Birrell C Faggioni R A double blind placebo controlled study to assess the pharmacokinetics safety and tolerability of multiple ascending intravenous doses of CAT 354 a recombinant human anti-IL 13 antibody, in subjects with moderate asthma European Respiratory Society 18th Annual Congress; 2008 Oct 3-7; Berlin 2008 3021"},{"key":"10.1002\/14651858.CD012929.pub2-BIB0128|cit128","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/1471-2466-10-3","article-title":"A phase 1 study evaluating the pharmacokinetics, safety and tolerability of repeat dosing with a human IL-13 antibody (CAT-354) in subjects with asthma","volume":"10","author":"Singh","year":"2010","journal-title":"BioMed Central Pulmonary Medicine"},{"issue":"6","key":"10.1002\/14651858.CD012929.pub2-BIB0129|cit129","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1007\/s12325-017-0525-8","article-title":"RPC4046, a novel anti-interleukin-13 antibody, blocks IL-13 binding to IL-13 alpha1 and alpha2 receptors: a randomized, double-blind, placebo-controlled, dose-escalation first-in-human study","volume":"34","author":"Tripp","year":"2017","journal-title":"Advances in Therapy"},{"issue":"9596","key":"10.1002\/14651858.CD012929.pub2-BIB0130|cit130","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1016\/S0140-6736(07)61600-6","article-title":"Effect of an interleukin-4 variant on late phase asthmatic response to allergen challenge in asthmatic patients: results of two phase 2a studies","volume":"370","author":"Wenzel","year":"2007","journal-title":"Lancet"},{"issue":"Suppl 50","key":"10.1002\/14651858.CD012929.pub2-BIB0131|cit131","first-page":"114s [746]","article-title":"AER 001 effects on antigen challenge in atopic asthmatic subjects [abstract]","volume":"28","author":"Wilbraham","year":"2006","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD012929.pub2-BIB0132|cit132","unstructured":"Effects of AER 001 administered by nebulization on antigen challenge in atopic asthmatics clinicaltrials.gov\/show\/NCT00535431"},{"issue":"9596","key":"10.1002\/14651858.CD012929.pub2-BIB0133|cit133","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1016\/S0140-6736(07)61600-6","article-title":"Effect of an interleukin-4 variant on late phase asthmatic response to allergen challenge in asthmatic patients: results of two phase 2a studies","volume":"370","author":"Wenzel","year":"2007","journal-title":"Lancet"},{"issue":"Suppl 51","key":"10.1002\/14651858.CD012929.pub2-BIB0134|cit134","first-page":"490s [2959]","article-title":"Inhaled IL-4\/IL-13 antagonist decreases response to antigen challenge in atopic asthmatic subjects","volume":"30","author":"Wilbraham","year":"2016","journal-title":"European Respiratory Journal"},{"issue":"Suppl 50","key":"10.1002\/14651858.CD012929.pub2-BIB0135|cit135","first-page":"114s [746]","article-title":"AER 001 effects on antigen challenge in atopic asthmatic subjects","volume":"28","author":"Wilbraham","year":"2006","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD012929.pub2-BIB0136|cit136","unstructured":"A phase iib study to investigate the treatment-sparing effects of Aerovant\u2122 (aer 001 inhalation powder) in asthma patients not fully controlled on current therapy - aerovant clinicaltrialsregister.eu\/ctr-search\/search?query=eudract_number:2007-006545-41"},{"key":"10.1002\/14651858.CD012929.pub2-BIB0137|cit137","unstructured":"A study of the treatment-sparing effects of AEROVANT\u2122 AER 001 inhalation powder in asthma patients, AEROTRIAL clinicaltrials.gov\/show\/NCT00801853"},{"key":"10.1002\/14651858.CD012929.pub2-BIB0138|cit138","first-page":"A6179","article-title":"A phase 2b study of inhaled pitrakinra, an IL-4\/IL-13 antagonist, successfully identified responder subpopulations of patients with uncontrolled asthma [abstract]","volume":"183","author":"Otulana","year":"2011","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1002\/14651858.CD012929.pub2-BIB0139|cit139","unstructured":"Wenzel SE Ind PW Otulana BA Bleecker ER Kuna P Yen YP Inhaled pitrakinra, an IL-4\/IL-13 antagonist, reduced exacerbations in patients with eosinophilic asthma [abstract] European Respiratory Society 20th Annual Congress; 2010 Sep 18-22; Barcelona 2010 P3980"},{"key":"10.1002\/14651858.CD012929.pub2-BIB0140|cit140","first-page":"A1321","article-title":"Responder analysis for FEV1 improvement with dupilumab in patients with persistent asthma and elevated eosinophil levels","volume":"189","author":"Castro","year":"2014","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1002\/14651858.CD012929.pub2-BIB0141|cit141","unstructured":"Efficacy, safety, and tolerability of dupilumab in patients with persistent moderate to severe eosinophilic asthma clinicaltrials.gov\/show\/NCT01312961"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD012929.pub2-BIB0142|cit142","first-page":"P13","article-title":"Dupilumab suppresses Th2 inflammation in adult asthma and atopic dermatitis","volume":"7","author":"Swanson","year":"2013","journal-title":"World Allergy Organization Journal"},{"issue":"2 Suppl","key":"10.1002\/14651858.CD012929.pub2-BIB0143|cit143","doi-asserted-by":"crossref","first-page":"AB85","DOI":"10.1016\/j.jaci.2013.12.321","article-title":"Exhaled nitric oxide (FENO) and t-helper 2 cell biomarkers: can they predict treatment response to dupilumab, an il-4ra antibody, in an eosinophilic asthma population?","volume":"133","author":"Swanson","year":"2014","journal-title":"Journal of Allergy and Clinical Immunology"},{"issue":"26","key":"10.1002\/14651858.CD012929.pub2-BIB0144|cit144","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1056\/NEJMoa1304048","article-title":"Dupilumab in persistent asthma with elevated eosinophil levels","volume":"368","author":"Wenzel","year":"2013","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD012929.pub2-BIB0145|cit145","first-page":"A6068","article-title":"Efficacy and safety of SAR231893\/REGN668 in patients with moderate-to-severe, persistent asthma and elevated eosinophil levels","volume":"187","author":"Wenzel","year":"2013","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1002\/14651858.CD012929.pub2-BIB0146|cit146","first-page":"A1323","article-title":"ACQ5 improvement with dupilumab in patients with persistent asthma and elevated eosinophil levels: responder analysis from a 12-week proof-of-concept placebo-controlled trial","volume":"189","author":"Wenzel","year":"2014","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"5 Suppl 1","key":"10.1002\/14651858.CD012929.pub2-BIB0147|cit147","doi-asserted-by":"crossref","first-page":"S50","DOI":"10.1016\/j.anai.2017.08.242","article-title":"Dupilumab reduces exacerbations and improves lung function in uncontrolled persistent asthma patients across baseline exacerbations","volume":"119","author":"Bernstein","year":"2017","journal-title":"Annals of Allergy, Asthma and Immunology"},{"issue":"1","key":"10.1002\/14651858.CD012929.pub2-BIB0148|cit148","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1111\/all.14611","article-title":"Dupilumab is effective in type 2-high asthma patients receiving high-dose inhaled corticosteroids at baseline","volume":"76","author":"Bourdin","year":"2020","journal-title":"Allergy"},{"issue":"2 Suppl 1","key":"10.1002\/14651858.CD012929.pub2-BIB0149|cit149","doi-asserted-by":"crossref","first-page":"AB112","DOI":"10.1016\/j.jaci.2017.12.357","article-title":"Exacerbation risk and type 2 inflammation in placebo patients during a phase 2b study of dupilumab in patients with uncontrolled persistent asthma","volume":"141","author":"Castro","year":"2018","journal-title":"Journal of Allergy and Clinical Immunology"},{"key":"10.1002\/14651858.CD012929.pub2-BIB0150|cit150","first-page":"A6489","article-title":"Dupilumab improves lung function inclusive of small airways in patients with uncontrolled persistent asthma: results from a Phase 2b clinical trial","volume":"193","author":"Castro","year":"2016","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1002\/14651858.CD012929.pub2-BIB0151|cit151","first-page":"A6491","article-title":"Dupilumab improves patient-reported outcomes in uncontrolled persistent asthma: results from a Phase 2b clinical trial","volume":"193","author":"Chanez","year":"2016","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"1","key":"10.1002\/14651858.CD012929.pub2-BIB0152|cit152","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.anai.2018.08.005","article-title":"Dupilumab improves symptoms, quality of life, and productivity in uncontrolled persistent asthma","volume":"122","author":"Corren","year":"2018","journal-title":"Annals of Allergy, Asthma and Immunology"},{"key":"10.1002\/14651858.CD012929.pub2-BIB0153|cit153","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.anai.2019.04.028","article-title":"Dupilumab improves asthma outcomes irrespective of frequency of previous asthma exacerbation history","volume":"123","author":"Corren","year":"2019","journal-title":"Annals of Allergy, Asthma & Immunology"},{"issue":"4 (Suppl)","key":"10.1002\/14651858.CD012929.pub2-BIB0154|cit154","doi-asserted-by":"crossref","first-page":"A26","DOI":"10.1016\/j.chest.2017.08.056","article-title":"Dupilumab improves asthma control and asthma-related quality of life in uncontrolled persistent asthma patients across all baseline exacerbation rates","volume":"152","author":"Corren","year":"2017","journal-title":"Chest"},{"issue":"Suppl","key":"10.1002\/14651858.CD012929.pub2-BIB0155|cit155","doi-asserted-by":"crossref","first-page":"4A","DOI":"10.1378\/chest.2280468","article-title":"Burden of persistent asthma in patients treated with medium-to high-dose inhaled corticosteroids: baseline data from a phase 2 clinical trial of dupilumab","volume":"148","author":"Corren","year":"2015","journal-title":"Chest"},{"key":"10.1002\/14651858.CD012929.pub2-BIB0156|cit156","first-page":"PA1530","article-title":"Dupilumab reduces severe exacerbation-related costs among asthma patients: results from a phase 2b trial","volume":"48","author":"Corren","year":"2016","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD012929.pub2-BIB0157|cit157","first-page":"108","article-title":"Dupilumab efficacy in severe asthma exacerbations by different baseline patient characteristics in patients with uncontrolled persistent asthma","volume":"72","author":"Fabbri","year":"2017","journal-title":"Allergy: European Journal of Allergy and Clinical Immunology"},{"issue":"Suppl 5","key":"10.1002\/14651858.CD012929.pub2-BIB0158|cit158","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1111\/imj.58_13578","article-title":"Dupilumab efficacy and effect on asthma control in patients with uncontrolled persistent asthma and comorbid chronic rhinosinusitis with or without nasal polyps","volume":"47","author":"Katelaris","year":"2017","journal-title":"Internal Medicine Journal"},{"key":"10.1002\/14651858.CD012929.pub2-BIB0159|cit159","first-page":"530","article-title":"Dupilumab improves lung function and reduces severe exacerbations in patients with uncontrolled persistent asthma with and without history of atopy","volume":"71","author":"Maspero","year":"2016","journal-title":"Allergy"},{"key":"10.1002\/14651858.CD012929.pub2-BIB0160|cit160","doi-asserted-by":"crossref","first-page":"AB190","DOI":"10.1016\/j.jaci.2015.12.752","article-title":"Dupilumab suppresses fractional exhaled nitric oxide (FeNO) and biomarkers of type 2 inflammation in adult patients with persistent uncontrolled asthma despite use of medium-to-high dose inhaled corticosteroids plus long-acting beta-agonists (ICS\/LABAS)","volume":"137","author":"Swanson","year":"2016","journal-title":"Journal of Allergy and Clinical Immunology"},{"issue":"10039","key":"10.1002\/14651858.CD012929.pub2-BIB0161|cit161","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(16)30307-5","article-title":"Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting beta2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial","volume":"388","author":"Wenzel","year":"2016","journal-title":"Lancet"},{"issue":"Suppl 59","key":"10.1002\/14651858.CD012929.pub2-BIB0162|cit162","first-page":"OA289","article-title":"A dose-ranging study of dupilumab in patients (pts) with uncontrolled asthma despite use of inhaled corticosteroids plus a long-acting beta-agonist (ICS\/LABA): final data","volume":"46","author":"Wenzel","year":"2015","journal-title":"European Respiratory Journal"},{"issue":"Suppl 60","key":"10.1002\/14651858.CD012929.pub2-BIB0163|cit163","first-page":"OA1798","article-title":"Dupilumab reduces severe exacerbations in periostin-high and periostin-low asthma patients","volume":"48","author":"Wenzel","year":"2016","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD012929.pub2-BIB0164|cit164","first-page":"A6362","article-title":"Dupilumab improves lung function and reduces severe exacerbations in uncontrolled asthmatics with baseline eosinophil levels above and below 300 cells\/mul","volume":"191","author":"Wenzel","year":"2015","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"1 Suppl 1","key":"10.1002\/14651858.CD012929.pub2-BIB0165|cit165","first-page":"S129","article-title":"Exposure-response analysis of dupilumab on forced expiratory volume in 1 second (FEV1) in uncontrolled persistent asthma","volume":"44","author":"Zhang","year":"2017","journal-title":"Journal of Pharmacokinetics and Pharmacodynamics"},{"issue":"Suppl 60","key":"10.1002\/14651858.CD012929.pub2-BIB0166|cit166","first-page":"OA251","article-title":"Dupilumab improves patient-reported outcomes in chronic sinusitis with nasal polyps patients with comorbid asthma: results from a phase 2a trial","volume":"48","author":"Bachert","year":"2016","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD012929.pub2-BIB0167|cit167","first-page":"S176","article-title":"Baseline characteristics of patients with chronic rhinosinusitis with nasal polyps (with and without asthma) enrolled in SINUS-52, a randomized, double-blind, phase 3 study of dupilumab","volume":"98","author":"Bachert","year":"2019","journal-title":"Laryngorhinotologie"},{"key":"10.1002\/14651858.CD012929.pub2-BIB0168|cit168","unstructured":"Banfield C Vincent M Kakkar T Chia M Thien F Cheah T Multiple dose study of AMG 317 in adults with asthma: pharmacokinetics and safety [abstract] European Respiratory Society 18th Annual Congress; 2008 Oct 3-7; Berlin 2008 3022"},{"issue":"6","key":"10.1002\/14651858.CD012929.pub2-BIB0169|cit169","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1164\/rccm.200312-1651OC","article-title":"Effects of treatment with anti-immunoglobulin E antibody omalizumab on airway inflammation in allergic asthma","volume":"170","author":"Djukanovic","year":"2004","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1002\/14651858.CD012929.pub2-BIB0170|cit170","unstructured":"Study evaluating IMA-638 in asthma clinicaltrials.gov\/show\/NCT00339872"},{"key":"10.1002\/14651858.CD012929.pub2-BIB0171|cit171","unstructured":"A study to assess bioavailability and pharmacokinetics of CAT- 354 clinicaltrials.gov\/show\/NCT00638989"},{"key":"10.1002\/14651858.CD012929.pub2-BIB0172|cit172","unstructured":"A phase 1 safety and pharmacokinetics study of AER 001 administered as a dry powder in asthmatic subjects clinicaltrials.gov\/show\/NCT00785668"},{"key":"10.1002\/14651858.CD012929.pub2-BIB0173|cit173","unstructured":"A phase 1, open-label study to investigate the pharmacokinetics of tralokinumab (CAT-354) in adolescents with asthma clinicaltrials.gov\/show\/NCT01592396"},{"key":"10.1002\/14651858.CD012929.pub2-BIB0174|cit174","unstructured":"A study of lebrikizumab in adolescent patients with uncontrolled asthma who are on inhaled corticosteroids and a second controller medication www.clinicaltrialsregister.eu\/ctr-search\/search?query=eudract_number:2012-000180-25"},{"key":"10.1002\/14651858.CD012929.pub2-BIB0175|cit175","unstructured":"A study of lebrikizumab in adolescent participants with uncontrolled asthma who are on inhaled corticosteroids and a second controller medication clinicaltrials.gov\/show\/NCT01875003"},{"key":"10.1002\/14651858.CD012929.pub2-BIB0176|cit176","unstructured":"A phase 1 study to evaluate the pharmacokinetics and tolerability of tralokinumab when delivered at different flow rates to healthy volunteers clinicaltrials.gov\/show\/NCT02085473"},{"issue":"12","key":"10.1002\/14651858.CD012929.pub2-BIB0177|cit177","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1111\/cea.13731","article-title":"A randomized, placebo-controlled trial evaluating effects of lebrikizumab on airway eosinophilic inflammation and remodelling in uncontrolled asthma (CLAVIER)","volume":"50","author":"Austin","year":"2020","journal-title":"Clinical and Experimental Allergy"},{"key":"10.1002\/14651858.CD012929.pub2-BIB0178|cit178","unstructured":"A study evaluating the effects of lebrikizumab on airway eosinophilic inflammation in participants with uncontrolled asthma clinicaltrials.gov\/show\/NCT02099656"},{"key":"10.1002\/14651858.CD012929.pub2-BIB0179|cit179","unstructured":"Long-term safety evaluation of dupilumab in patients with asthma www.clinicaltrialsregister.eu\/ctr-search\/search?query=eudract_number:2013-003856-19"},{"key":"10.1002\/14651858.CD012929.pub2-BIB0180|cit180","unstructured":"Long-term safety evaluation of dupilumab in patients with asthma (LIBERTY ASTHMA TRAVERSE) clinicaltrials.gov\/show\/NCT02134028"},{"key":"10.1002\/14651858.CD012929.pub2-BIB0181|cit181","unstructured":"A single-arm study to evaluate administration of lebrikizumab by participants or caregivers in the home setting clinicaltrials.gov\/show\/NCT02546869"},{"key":"10.1002\/14651858.CD012929.pub2-BIB0182|cit182","unstructured":"A study to evaluate the safety of tralokinumab in adults and adolescents with uncontrolled asthma clinicaltrials.gov\/show\/NCT02902809"},{"issue":"5 Suppl","key":"10.1002\/14651858.CD012929.pub2-BIB0183|cit183","doi-asserted-by":"crossref","first-page":"S40","DOI":"10.1016\/j.anai.2018.09.129","article-title":"Efficacy of subcutaneous dupilumab a human anti-interleukin-4 receptor alpha monoclonal antibody for moderate-to-severe uncontrolled asthmatics","volume":"121","author":"Nsouli","year":"2018","journal-title":"Annals of Allergy, Asthma and Immunology"},{"key":"10.1002\/14651858.CD012929.pub2-BIB0184|cit184","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1111\/j.1365-2125.2010.03647.x","article-title":"An open-label, single-dose bioavailability study of the pharmacokinetics of CAT-354 after subcutaneous and intravenous administration in healthy males","volume":"69","author":"Oh","year":"2010","journal-title":"British Journal of Clinical Pharmacology"},{"key":"10.1002\/14651858.CD012929.pub2-BIB0185|cit185","doi-asserted-by":"crossref","unstructured":"Oh CK Fraggioni R Roskos L Dialino-Felix A Smith H Wilson R An open-label, parallel-group, bioavailability study to assess the pharmacokinetics of CAT-354 following subcutaneous and intravenous administration in healthy subjects [abstract] American Thoracic Society International Conference; 2009 May 15-20 San Diego 2009 A2813 [Poster #J81]","DOI":"10.1164\/ajrccm-conference.2009.179.1_MeetingAbstracts.A2813"},{"key":"10.1002\/14651858.CD012929.pub2-BIB0186|cit186","unstructured":"Parsey M Moveck R Allison M Pearlman D Marbury T Furfine E A phase I study of IL-4\/13 trap in patients with clinically stable, mild to moderate asthma [abstract] American Thoracic Society 100th International Conference; 2004 May 21-26; Orlando 2004 D81"},{"issue":"Suppl 61","key":"10.1002\/14651858.CD012929.pub2-BIB0187|cit187","first-page":"PA3550","article-title":"Dupilumab improves lung function and reduces severe exacerbations in uncontrolled persistent asthma patients with ongoing allergic rhinitis","volume":"50","author":"Weinstein","year":"2017","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD012929.pub2-BIB0188|cit188","unstructured":"Evaluation of dupilumab's effects on airway inflammation in patients with asthma www.clinicaltrialsregister.eu\/ctr-search\/search?query=eudract_number:2015-001572-22"},{"key":"10.1002\/14651858.CD012929.pub2-BIB0189|cit189","unstructured":"Pilot study in patients with symptomatic steroid-naive asthma clinicaltrials.gov\/ct2\/show\/NCT00024544"},{"key":"10.1002\/14651858.CD012929.pub2-BIB0190|cit190","unstructured":"A study of lebrikizumab in patients with severe asthma who depend on oral corticosteroids www.clinicaltrialsregister.eu\/ctr-search\/search?query=eudract_number:2012-000190-24"},{"key":"10.1002\/14651858.CD012929.pub2-BIB0191|cit191","unstructured":"A study of lebrikizumab (RO5490255) in participants with severe oral corticosteroids (OCS) dependent asthma clinicaltrials.gov\/show\/NCT01987492"},{"key":"10.1002\/14651858.CD012929.pub2-BIB0192|cit192","unstructured":"Evaluation of dupilumab in children with uncontrolled asthma (VOYAGE) clinicaltrials.gov\/show\/NCT02948959"},{"key":"10.1002\/14651858.CD012929.pub2-BIB0193|cit193","unstructured":"Study of REGN3500 and dupilumab in patients with asthma clinicaltrials.gov\/show\/NCT03112577"},{"key":"10.1002\/14651858.CD012929.pub2-BIB0194|cit194","unstructured":"Evaluation of SAR440340 and AS combination therapy with dupilumab in moderate-to-severe asthma patients clinicaltrials.gov\/show\/NCT03387852"},{"key":"10.1002\/14651858.CD012929.pub2-BIB0195|cit195","unstructured":"Efficacy and safety study of dupilumab in patients with persistent asthma clinicaltrials.gov\/show\/nct03782532"},{"issue":"5","key":"10.1002\/14651858.CD012929.pub2-BIB0196|cit196","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1111\/all.14235","article-title":"Efficacy and safety of treatment with biologicals (benralizumab, dupilumab and omalizumab) for severe allergic asthma: a systematic review for the EAACI Guidelines - recommendations on the use of biologicals in severe asthma","volume":"75","author":"Agache","year":"2020","journal-title":"Allergy"},{"issue":"5","key":"10.1002\/14651858.CD012929.pub2-BIB0197|cit197","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1111\/all.14221","article-title":"Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI Guidelines - recommendations on the use of biologicals in severe asthma","volume":"75","author":"Agache","year":"2020","journal-title":"Allergy"},{"issue":"12","key":"10.1002\/14651858.CD012929.pub2-BIB0198|cit198","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1111\/cea.13731","article-title":"A randomized, placebo-controlled trial evaluating effects of lebrikizumab on airway eosinophilic inflammation and remodelling in uncontrolled asthma (CLAVIER)","volume":"50","author":"Austin","year":"2020","journal-title":"Clinical and Experimental Allergy"},{"issue":"2","key":"10.1002\/14651858.CD012929.pub2-BIB0199|cit199","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.anai.2013.12.013","article-title":"Biologic targeted therapy in allergic asthma","volume":"112","author":"Bice","year":"2014","journal-title":"Annals of Allergy, Asthma and Immunology"},{"key":"10.1002\/14651858.CD012929.pub2-BIB0200|cit200","unstructured":"British Lung Foundation Asthma Statistics statistics.blf.org.uk\/asthma"},{"key":"10.1002\/14651858.CD012929.pub2-BIB0201|cit201","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1067\/mai.2001.117880","article-title":"Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma","volume":"108","author":"Busse","year":"2001","journal-title":"Journal of Allergy and Clinical Immunology"},{"key":"10.1002\/14651858.CD012929.pub2-BIB0202|cit202","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1165\/rcmb.2008-0162OC","article-title":"Interleukin-13 augments bronchial smooth muscle contractility with an up-regulation of RhoA protein","volume":"40","author":"Chiba","year":"2009","journal-title":"American Journal of Respiratory Cell and Molecular Biology"},{"key":"10.1002\/14651858.CD012929.pub2-BIB0203|cit203","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3109\/08830189809084486","article-title":"Interleukin-4 and Interleukin-13: their similarities and discrepancies","volume":"17","author":"Chomarat","year":"1998","journal-title":"International Reviews of Immunology"},{"key":"10.1002\/14651858.CD012929.pub2-BIB0204|cit204","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1056\/NEJMoa1106469","article-title":"Lebrikizumab treatment in adults with asthma","volume":"365","author":"Corren","year":"2011","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"10.1002\/14651858.CD012929.pub2-BIB0205|cit205","first-page":"pii: 00024","article-title":"Management of the patient with eosinophilic asthma: a new era begins","volume":"1","author":"De Groot","year":"2015","journal-title":"European Respiratory Journal Open Research"},{"key":"10.1002\/14651858.CD012929.pub2-BIB0206|cit206","unstructured":"European Medicines Agency Summary of product characteristics - Dupixent www.ema.europa.eu\/en\/documents\/product-information\/dupixent-epar-product-information_en.pdf."},{"key":"10.1002\/14651858.CD012929.pub2-BIB0207|cit207","unstructured":"European Respiratory Society Forum of international respiratory societies. The global impact of respiratory disease - second edition firsnet.org\/images\/publications\/The_Global_Impact_of_Respiratory_Disease.pdf"},{"issue":"9","key":"10.1002\/14651858.CD012929.pub2-BIB0208|cit208","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010834.pub3","article-title":"Anti-IL5 therapies for asthma","author":"Farne","year":"2017","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD012929.pub2-BIB0209|cit209","unstructured":"Highlights of prescribing information. Dupixent www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/761055s007lbl.pdf"},{"key":"10.1002\/14651858.CD012929.pub2-BIB0210|cit210","unstructured":"Global strategy for asthma management and prevention 2020 ginasthma.org\/gina-reports\/"},{"key":"10.1002\/14651858.CD012929.pub2-BIB0211|cit211","unstructured":"Global Asthma Network The Global Asthma Report 2014. Auckland, New Zealand www.globalasthmareport.org\/resources\/Global_Asthma_Report_2014.pdf"},{"key":"10.1002\/14651858.CD012929.pub2-BIB0212|cit212","unstructured":"McMaster University (developed by Evidence Prime) GRADEpro GDT 2015"},{"key":"10.1002\/14651858.CD012929.pub2-BIB0213|cit213","first-page":"781","article-title":"Efficacy and safety of lebrikizumab in patients with uncontrolled asthma (LAVOLTA I and LAVOLTA II): replicate, phase 3, randomised, double-blind, placebo-controlled trials","volume":"4","author":"Hanania","year":"2016","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD012929.pub2-BIB0214|cit214","unstructured":"Higgins JPT Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from training.cochrane.org\/handbook\/archive\/v5.1"},{"issue":"6","key":"10.1002\/14651858.CD012929.pub2-BIB0215|cit215","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1097\/ACI.0000000000000108","article-title":"Anti-interleukin 4 and 13 for asthma treatment in the era of endotypes","volume":"14","author":"Kau","year":"2014","journal-title":"Current Opinion in Allergy and Clinical Immunology"},{"issue":"1","key":"10.1002\/14651858.CD012929.pub2-BIB0216|cit216","first-page":"e0211790","article-title":"A meta-analysis of anti-interleukin-13 monoclonal antibodies for uncontrolled asthma","volume":"14","author":"Li","year":"2019","journal-title":"Meta-analysis: PLOS One"},{"key":"10.1002\/14651858.CD012929.pub2-BIB0217|cit217","doi-asserted-by":"crossref","first-page":"534-43","DOI":"10.1038\/nri1128","article-title":"Regulation of IL4 gene expression by T cells and therapeutic perspectives","volume":"3","author":"Li-Weber","year":"2003","journal-title":"Nature Reviews. Immunology"},{"key":"10.1002\/14651858.CD012929.pub2-BIB0218|cit218","unstructured":"Higgins J Lasserson T Chandler J Tovey D Thomas J Flemyng E Standards for the conduct and reporting of new Cochrane Intervention Reviews, reporting of protocols and the planning, conduct and reporting of updates (version March 2020) community.cochrane.org\/mecir-manual"},{"issue":"7","key":"10.1002\/14651858.CD012929.pub2-BIB0219|cit219","doi-asserted-by":"publisher","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLOS Medicine"},{"key":"10.1002\/14651858.CD012929.pub2-BIB0220|cit220","unstructured":"Evaluation of dupilumab's effects on airway inflammation in patients with asthma (EXPEDITION) clinicaltrials.gov\/ct2\/show\/NCT02573233"},{"key":"10.1002\/14651858.CD012929.pub2-BIB0221|cit221","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.jaci.2013.06.029","article-title":"Validation and psychometric properties of the Asthma Control Questionnaire among children","volume":"133","author":"Nguyen","year":"2014","journal-title":"Journal of Allergy and Clinical Immunology"},{"key":"10.1002\/14651858.CD012929.pub2-BIB0222|cit222","first-page":"567","article-title":"Dose-ranging study of lebrikizumab in asthmatic patients not receiving inhaled steroids","volume":"132","author":"Noonan","year":"2013","journal-title":"Academy of Allergy, Asthma and Immunology"},{"key":"10.1002\/14651858.CD012929.pub2-BIB0223|cit223","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1056\/NEJMoa1403290","article-title":"Mepolizumab treatment in patients with severe eosinophilic asthma","volume":"371","author":"Ortega","year":"2014","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD012929.pub2-BIB0224|cit224","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.intimp.2010.11.020","article-title":"Role of the Mac-1 and VLA-4 integrins, and concomitant Th2-cytokine production, in nitric oxide modulated eosinophil migration from bone marrow to lungs in allergic mice","volume":"11","author":"Pelaquini","year":"2011","journal-title":"International Immunopharmacology"},{"key":"10.1002\/14651858.CD012929.pub2-BIB0225|cit225","unstructured":"Royal College of Physicians Why asthma still kills: the National Review of Asthma Deaths (NRAD) Confidential Enquiry Report rcplondon.ac.uk\/projects\/outputs\/why-asthma-still-kills"},{"key":"10.1002\/14651858.CD012929.pub2-BIB0226|cit226","unstructured":"Nordic Cochrane Centre, The Cochrane Collaboration Review Manager 5 (RevMan 5) 2014"},{"key":"10.1002\/14651858.CD012929.pub2-BIB0227|cit227","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.jaci.2008.01.005","article-title":"Increased sputum viscosity and bronchial biopsy IL-13 expression in severe asthma","volume":"121","author":"Saha","year":"2008","journal-title":"Journal of Allergy and Clinical Immunology"},{"key":"10.1002\/14651858.CD012929.pub2-BIB0228|cit228","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1034\/j.1399-3003.1999.14a06.x","article-title":"What are minimal important changes for asthma measures in a clinical trial?","volume":"14","author":"Santanello","year":"1999","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD012929.pub2-BIB0229|cit229","doi-asserted-by":"crossref","first-page":"14170","DOI":"10.1073\/pnas.1009426107","article-title":"Roles of epithelial cell-derived periostin in TGF-b activation, collagen production, and collagen gel elasticity in asthma","volume":"107","author":"Sidhu","year":"2010","journal-title":"Proceedings of the National Academy of Sciences"},{"key":"10.1002\/14651858.CD012929.pub2-BIB0230|cit230","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1111\/j.1398-9995.2006.01254.x","article-title":"Extent, patterns, and burden of uncontrolled disease in severe or difficult-to-treat asthma","volume":"62","author":"Sullivan","year":"2007","journal-title":"Allergy"},{"issue":"2","key":"10.1002\/14651858.CD012929.pub2-BIB0231|cit231","doi-asserted-by":"crossref","first-page":"AB140","DOI":"10.1016\/j.jaci.2020.12.507","article-title":"Effect of dupilumab treatment on blood eosinophil levels in patients with asthma, chronic rhinosinusitis with nasal polyps (CRSwNP), eosinophilic esophagitis (EoE), or atopic dermatitis (AD)","volume":"147","author":"Wechsler","year":"2021","journal-title":"Journal of Allergy and Clinical Immunology"},{"key":"10.1002\/14651858.CD012929.pub2-BIB0232|cit232","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1056\/NEJMoa1304048","article-title":"Dupilumab in persistent asthma with elevated eosinophil levels","volume":"368","author":"Wenzel","year":"2013","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD012929.pub2-BIB0233|cit233","doi-asserted-by":"crossref","first-page":"15858","DOI":"10.1073\/pnas.0707413104","article-title":"Genome-wide profiling identifies epithelial cell genes associated with asthma and with treatment response to corticosteroids","volume":"104","author":"Woodruff","year":"2007","journal-title":"Proceedings of the National Academy of Sciences"},{"key":"10.1002\/14651858.CD012929.pub2-BIB0234|cit234","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1159\/000113517","article-title":"Interleukin-4 and interleukin-13 enhance human bronchial smooth muscle cell proliferation","volume":"146","author":"Bosse","year":"2008","journal-title":"International Archives of Allergy and Immunology"},{"issue":"1","key":"10.1002\/14651858.CD012929.pub2-BIB0235|cit235","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD012929","article-title":"Anti-interleukin-13 and anti-interleukin-4 agents versus placebo, anti-interleukin-5 or anti-immunoglobulin-E agents, for children and adults with asthma","author":"Edwards","year":"2018","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2022,3,16]],"date-time":"2022-03-16T23:50:44Z","timestamp":1647474644000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD012929.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Airways Group","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2021,10,19]]},"references-count":235,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2021,10]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd012929.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,19]]}}}